Product
Decitabine/cedazuridine
2 clinical trials
9 indications
Indication
Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromeIndication
Chronic Myelomonocytic LeukemiaIndication
MDS/MPN-unclassifiableIndication
Hematopoietic stem cell transplantationIndication
MesotheliomaIndication
Malignant MesotheliomaIndication
BAP1-associated malignanciesClinical trial
A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap SyndromesStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Phase II Evaluation of Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage MesotheliomaStatus: Recruiting, Estimated PCD: 2025-12-01